Collagen Regeneration
Connective tissue & autoimmune collagen disorders
Pre-clinicalActive
Key Facts
Indication
Connective tissue & autoimmune collagen disorders
Phase
Pre-clinical
Status
Active
Company
About Frame Bio
Frame Bio is an early-stage biotech (founded 2021) pioneering targeted therapies for bone and connective tissue diseases. Its core technology utilizes a licensed extracellular vesicle (yEV™) delivery system from Mercury Bio to precisely transport molecular payloads like BMP-2 to injured tissues. The company is developing a pre-clinical pipeline aimed at collagen regeneration and bone repair, targeting large, underserved patient populations with chronic structural diseases. Frame Bio operates as a private, pre-revenue entity based in San Francisco.
View full company profile